	US 12,391,925 B2
	Prevention and/or treatment of type 1 diabetes by augmentation of myeloid suppressor cell activity
Thomas Ichim, San Diego, CA (US); and Amit Patel, Salt Lake City, UT (US)
Assigned to Creative Medical Technologies, Inc., Phoenix, AZ (US)
Filed by CREATIVE MEDICAL TECHNOLOGIES, INC., Phoenix, AZ (US)
Filed on Jun. 8, 2022, as Appl. No. 17/835,818.
Claims priority of provisional application 63/208,249, filed on Jun. 8, 2021.
Prior Publication US 2022/0389385 A1, Dec. 8, 2022
Int. Cl. C12N 5/0775 (2010.01); A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/41 (2025.01); A61L 27/38 (2006.01); A61P 3/10 (2006.01); C12N 5/078 (2010.01)

CPC C12N 5/0662 (2013.01) [A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/416 (2025.01); A61L 27/3834 (2013.01); A61P 3/10 (2018.01); C12N 5/0634 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05)]

14 Claims

1. A method of treating type 1 diabetes comprising the steps of: a) selecting a patient suffering from type 1 diabetes; b) extracting an immune cell population comprising T regulatory cells from said patient; c) exposing said immune cell population to interleukin-2 (IL-2) and conditioned media from mesenchymal stem cells derived from a source selected from the group consisting of: placental tissue, amniotic membrane, umbilical cord tissue, fallopian tube tissue, and subepithelial umbilical cord tissue and treated with interferon gamma; d) separating T regulatory cells from said immune cell population and administering said T regulatory cells back into said patient in need of treatment; and e) administering an agent capable of enhancing the number and/or activity of myeloid suppressor cells selected from the group consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) and Bacillus Calmette-Guérin (BCG) vaccine into said patient.